From Reuters, April 25:
Amgen (AMGN.O), on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs.
Amgen, based in Thousand Oaks, California, said the plans bring its total investment in central Ohio to more than $1.4 billion, creating 750 jobs.Other drugmakers committing recently to U.S. manufacturing expansions include Eli Lilly, Novartis, Roche, and Johnson & Johnson....
....MUCH MORE
The one that really stood out for us was "Swiss pharmaceuticals company Roche announces $50B investment in US over next 5 years" because it followed so closely on the warning from the EFPIA (also because of the 50 large, that's a lot of money, no matter who you are):
...April 13's "Pharma CEOs alert President von der Leyen to risk of exodus to the US" on The European Federation of Pharmaceutical Industries and Associations:
Here's who "These folks" are:
- Abbvie
- Almiral
- Amgen
- Astellas
- AstraZeneca
- Bayer
- Biogen
- Boehringer Ingleheim
- Bristol Myers Squibb
- Dai Ichi Sankyo
- Gilead
- Grunenthal
- GSK
- Johnson&Johnson
- LEO
- Lilly
- Merck
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Takeda
- Teva
And many more. My thought when seeing the membership list was: I have heard of these companies.